Dou, Xiaoyang
Xiao, Yu
Shen, Chao
Wang, Kitty
Wu, Tong https://orcid.org/0000-0001-9968-9909
Liu, Chang
Li, Yini https://orcid.org/0000-0003-2213-0650
Yu, Xianbin
Liu, Jun https://orcid.org/0000-0002-2498-9963
Dai, Qing https://orcid.org/0000-0002-8578-1568
Pajdzik, Kinga
Ye, Chang https://orcid.org/0000-0003-0236-5671
Ge, Ruiqi
Gao, Boyang
Yu, Jianhua https://orcid.org/0000-0002-0326-3223
Sun, Shuying https://orcid.org/0000-0002-8449-7370
Chen, Mengjie https://orcid.org/0000-0003-1579-087X
Chen, Jianjun https://orcid.org/0000-0003-3749-2902
He, Chuan https://orcid.org/0000-0003-4319-7424
Funding for this research was provided by:
Foundation for the National Institutes of Health (RM1 HG008935)
Foundation for the National Institutes of Health (R01 HL155909)
Foundation for the National Institutes of Health (R01 ES030546)
Foundation for the National Institutes of Health (R01 CA251150)
Foundation for the National Institutes of Health (R01 NS107347)
Foundation for the National Institutes of Health (RF1 NS113820)
Foundation for the National Institutes of Health (RF1 NS127925)
Foundation for the National Institutes of Health (R01 AG078948)
Foundation for the National Institutes of Health (R01 HG012927)
Foundation for the National Institutes of Health (R01 CA236399)
Foundation for the National Institutes of Health (R01 CA243386)
Foundation for the National Institutes of Health (R01 CA271497)
Foundation for the National Institutes of Health (R01 DK124116)
National Science Foundation (NSF 2016307)
Article History
Received: 15 June 2022
Accepted: 21 July 2023
First Online: 28 August 2023
Competing interests
: C.H. is a scientific founder, a member of the scientific advisory board and equity holder of Aferna Bio, Inc. and AccuaDX Inc., a scientific co-founder and equity holder of Accent Therapeutics, Inc., and a member of the scientific advisory board of Rona Therapeutics. T.W. is a shareholder of AccuraDX, Inc. The other authors declare no competing interests.